SOURCE: TSRL, Inc.

TSRL, Inc.

June 24, 2014 12:01 ET

TSRL Announces Receipt of $4.2 Million in New SBIR Funding

ANN ARBOR, MI--(Marketwired - Jun 24, 2014) - Therapeutic Systems Research Laboratories, Inc. (TSRL) announced today that the company was awarded two Phase I and one Phase II Small Business Innovation Research (SBIR) grants from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grants are supporting the preclinical research of the company's broad-spectrum antiviral prodrug program, as well as the development of an antiviral therapeutic for the treatment of adenovirus infections. TSRL will be receiving up to $4.2 million over the next 3 years through these SBIR grants. In addition, initial manufacturing scale up of a lead candidate and preclinical pharmacology testing has been performed for TSRL by NIAID under the NIAID preclinical services contracts program.

TSRL, Inc. is a privately held oral drug delivery specialty firm focused on R&D efforts to enhance the targeted delivery of investigational and marketed therapeutics. More detailed information about TSRL is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, Vice President for Business Development, 734 663-4233 x236, elipka@tsrlinc.com.

Contact Information

  • Dr. Elke Lipka
    Vice President of Business Development
    734 663-4233 x236
    Email Contact